A Parallel Phase I/II Clinical Trial Design for Combination Therapies
暂无分享,去创建一个
Xuelin Huang | Donald A Berry | D. Berry | Swati Biswas | J. Issa | Y. Oki | Xuelin Huang | Jean-Pierre Issa | Swati Biswas | Yasuhiro Oki
[1] Peter F Thall,et al. Dose‐Finding with Two Agents in Phase I Oncology Trials , 2003, Biometrics.
[2] L. J. Wei,et al. The Randomized Play-the-Winner Rule in Medical Trials , 1978 .
[3] R Simon,et al. Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Issa,et al. Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia , 2003, Cancer.
[5] B E Storer,et al. Design and analysis of phase I clinical trials. , 1989, Biometrics.
[6] Jorge Cortes,et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.
[7] D. Berry,et al. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.
[8] R Simon,et al. Selecting drug combinations based on total equivalent dose (dose intensity) , 1990, Journal of the National Cancer Institute.
[9] Anastasia Ivanova,et al. Two‐Dimensional Dose Finding in Discrete Dose Space , 2005, Biometrics.
[10] R. Simon,et al. Selecting combinations of chemotherapeutic drugs to maximize dose intensity. , 1991, Journal of biopharmaceutical statistics.
[11] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[12] R. Hoffman,et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. , 2000, Blood.
[13] D. Berry. Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.
[14] Peter F Thall,et al. Seamlessly Expanding a Randomized Phase II Trial to Phase III , 2002, Biometrics.
[15] R. Pearl. Biometrics , 1914, The American Naturalist.
[16] E. Gehan,et al. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.
[17] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[18] M. Zelen,et al. Play the Winner Rule and the Controlled Clinical Trial , 1969 .
[19] Donald A. Berry,et al. Statistical Innovations in Cancer Research , 2003 .
[20] Shyamal D Peddada,et al. Designs for Single‐ or Multiple‐Agent Phase I Trials , 2004, Biometrics.
[21] D. Berry. Bayesian Statistics and the Efficiency and Ethics of Clinical Trials , 2004 .